Breath Therapeutics
GermanyWho owns Breath Therapeutics?
Breath Therapeutics is a German Biotech company, now owned by Zambon, which acquired it in 2019 from Sofinnova Partners and Gimv.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Fully exited in 2019 to Zambon.
- ·Average hold across 2 realized cycles: 3 years.
Ownership history
2 ownership periods · co-invest detected
Sofinnova Partners sold Breath Therapeutics to Zambon in 2019 after 3 years.
Gimv sold Breath Therapeutics to Zambon in 2019 after 3 years.
More from Sofinnova Capital VIII
Other portfolio companies in the same fund.
Switzerland· 2017
US· 2016
UK· 2016
France· 2016US· 2016
Italy· 2015More PE-backed in Biotech
Comparable biotech deals from other GPs.
Questions
Who owns Breath Therapeutics?
Breath Therapeutics is now owned by Zambon, which acquired it in 2019 from Sofinnova Partners and Gimv.
When did Zambon acquire Breath Therapeutics?
Zambon acquired Breath Therapeutics in 2019, buying from Sofinnova Partners and Gimv.
Who did Breath Therapeutics sell to?
Sofinnova Partners and Gimv sold Breath Therapeutics to Zambon in 2019 (Trade Sale).
Who has owned Breath Therapeutics over time?
Breath Therapeutics has been through 2 private-equity ownership periods: Sofinnova Partners · via Sofinnova Capital VIII · 2016–2019 · sold to Zambon · (Trade Sale); Gimv · 2016–2019 · sold to Zambon · (Trade Sale).